AEZS (MC $67 M) (Cash $45.7M ) FDA Decision on Nov 5= 300% Potential !

[ablktlnu73]

This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .

FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !

AEZS could run to $3-5 before FDA decision in early November .GL


Aeterna Zentaris (AEZS)

Market Cap: $67 M
Cash: $45.7 M
Price: $1.18

Shares Out: 56.5 M


Insider activity:
http://canadianinsider.com/node/7?menu_tickersearch=aez

Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD

[abkekecifip]

Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD


Pipeline
http://www.aezsinc.com/en/page.php?p=20


New Presentation
http://www.aezsinc.com/pdfdyn/AEZS presentation June 2014.pdf



MACRILEN™(macimorelin)

•Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN™ as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency

[abivexi]

Still a great entry point at this ridiculous low price ...

Buy rating and a 12-month price target of $3.00 per share

In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share.

Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA review. Macrilen is an Adult Growth Hormone Deficiency (AGHD) detection treatment, expected to be approved by the PDUFA date of November 25 and acquired in-licenses approved the treatment expected by the end of 2014.

The Wainwright note also focused on Zoptarelin doxorubicin, with most sourced guidance anticipating its release in 2018. Zoptarelin is a high-purpose endometrial cancer treatment, with expected high growth into AEterna's share price over time.

[acajuxinij]

AEZS runnning higher guys

PDUFA date on November 5

Market Cap just $75 M
Cash : $40 M

Cheapest FDA play out there for 2014


Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target !!!

In a research report issued Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target, which represents a potential upside of 400% from where the stock is currently trading. The report follows the company’s second-quarter update, which was released last week.

Kolbert noted, “Aetrena Zentaris reported the quarter. The company had an operating loss of $5M and finished the year with just under $40M in cash. We believe management is executing a productive turnaround of the business. The launch of Macrilen should happen in early 2015 and we are hopeful to see this product build traction over time in the traumatic brain injury marketplace. We extend our model to 2020 and assume clinical success with AEZS in endometrial cancer (US & EU).” Furthermore, the analyst noted, “The New Drug Application (NDA) for Macrilen is submitted (11.5.2014 PDUFA) and the review process is now underway. The phase 3 data demonstrated that the compound has the potential to become the first orally approved diagnostic test for AGHD, with accuracy comparable to available testing procedures. We also believe that its utility in traumatic brain injury can be substantial.”

The analyst explained his price target: “We see the primary valuation drivers at AEZS being based on both AEZS-108 (doxorubicin conjugate) and AEZS-130 (diagnostic). We project these revenues in our models. We use a 30% discount rate and triangulate FCFF, discounted EPS, and SOP models. Our model assumes dilution and uses a forecast share count for 2020. The equal weighted average of these metrics points to a $5.00 per share target.”

[admin]

Dilution (already closed) here created a fantastic buying opportunity for Gamblers . Big Phase 3 data for Endometrial Cancer coming in April this could push the sp significantly higher . AEZS is Trading below so the downside is very limited thats why the stock is very attractive for Gamblers .GL


Market Cap : $46 Million
Cash: ~ $65 Million

Price: $0.51



Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data

In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.

Kolbert said, ?Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.?
---------------

Zoptarelin Doxorubicin

?Potentially the first FDA approved medical therapy for treating
recurrent endometrial cancer

Interim results in H1-2015 (~128 events)

Significant Market Opportunity Potential

Estimated Potential Annual Market Value
Medical Therapy Treating Recurrent Endometrial Cancer

North America $300?$400 Million

Europe $150?$250 Million